Color Hereditary Cancer Test
A multi-cancer genetic test evaluating key hereditary risks—including breast, ovarian, and colorectal cancers—to help guide diagnosis and prevention.
Accessed through the Ovarian Cancer Sponsored Testing Program•Sponsored by AstraZeneca, GSK, Merck, Genentech, Ovarian Cancer Research Alliance•Performed by Color Health
Designed to support clinical decision-making and ordering in your practice.
For healthcare providers
Overview
This no-cost hereditary cancer testing program, funded by AstraZeneca, GSK, Merck, and Genentech in partnership with the Ovarian Cancer Research Alliance, supports clinical risk assessment for patients who may carry pathogenic variants associated with ovarian, breast, uterine/endometrial, colorectal, or prostate cancers. Testing is performed by Color Health using an at-home saliva collection kit, and results include access to certified genetic counselors to facilitate clinical interpretation and next steps. The program removes financial barriers entirely, allowing you to integrate hereditary cancer evaluation into your workflow without cost concerns for the patient.
When to consider this test
Patient selection
- (Note: This program does not require an outside provider to initiate testing. Color’s clinical team handles authorization.)
- Providers may become involved after testing, when patients share results or need follow-up evaluation.
- Providers who receive results through their patients may use them to guide counseling, surveillance, or treatment decisions.
- No action is required from providers to order testing — Color’s internal clinician network reviews and approves all test requests submitted through the program.
Workflow
How to use this program
- 1
Discuss Program
Talk with eligible patients about the OCRA free genetic testing program and how at-home testing through Color Health may help clarify hereditary cancer risk. Share the link so they can apply directly.
- 2
Support Testing
Answer patient questions, encourage them to complete the Color Health questionnaire, and be available if they need help understanding whether the program fits their situation.
- 3
Review Results
If your patient feels comfortable sharing their results, use the findings to guide risk assessment, surveillance planning, and referrals for further evaluation or management as appropriate.
Billing overview
Program billing
For eligible patients, the sponsor has arrangements with the laboratory that may reduce or cover some or all of the patient's out-of-pocket cost. Actual cost and patient responsibility vary by program criteria. Refer to lab or sponsor materials for details.
Quality & privacy
Laboratory quality & data handling
Testing is performed by Color Health, a CLIA-certified laboratory (CLIA 05D2081492) and College of American Pathologists (CAP) certified laboratory (CAP 8975161). Your sample is processed using validated methods and quality controls to support reliable genetic results.
Your health information is handled under privacy and security practices that are intended to align with applicable regulations. For program- and lab-specific details, review the privacy information provided by the laboratory and sponsor.
FAQ
Frequently asked questions
Which patients are appropriate for the OCRA sponsored hereditary cancer testing program?
The program is designed for individuals at increased risk for ovarian or gynecologic cancers, as well as those who may carry variants associated with other hereditary cancer syndromes. If your patient meets the program's eligibility criteria, they can receive hereditary cancer testing at no cost. The panel also evaluates inherited risk for breast, uterine/endometrial, colorectal, and prostate cancers, broadening its clinical utility beyond gynecologic oncology alone.
What does the OCRA hereditary cancer test panel cover and who performs the testing?
Testing is performed by Color Health and evaluates hereditary cancer risk across multiple cancer types, including ovarian, breast, uterine/endometrial, colorectal, and prostate cancers. The program uses an at-home saliva collection kit shipped directly to the patient. Results are accompanied by access to certified genetic counselors, supporting clinical decision-making and patient education.
What specimen is required and how is the OCRA genetic testing kit delivered?
The program utilizes an at-home saliva collection kit processed by Color Health. The kit is shipped directly to the patient, eliminating the need for an in-office blood draw or lab visit. This streamlined specimen collection may improve patient compliance and reduce logistical burden on your practice.
Is genetic counseling included with the OCRA hereditary cancer testing program?
Yes. The program provides access to certified genetic counselors at no cost to the patient. Counselors are available to assist with results interpretation, variant classification context, and guidance on cascade testing for at-risk family members. This embedded counseling support can facilitate more informed clinical decisions regarding surveillance, risk reduction, and treatment planning.
Is there any prescribing or purchase obligation when ordering through the OCRA sponsored genetic testing program?
No. Ordering through the OCRA hereditary cancer testing program carries no prescribing or purchase obligation whatsoever. The program is funded entirely by AstraZeneca, GSK, Merck, and Genentech, in partnership with the Ovarian Cancer Research Alliance, and the testing is provided at no cost to eligible patients. It is a clinical resource, not a commercial commitment.
Is the OCRA sponsored hereditary cancer testing program available outside the United States?
The OCRA hereditary cancer testing program is currently available to eligible individuals in the United States. Clinicians practicing outside the US should explore alternative sponsored or institutional testing pathways for their patients.
Which patients are eligible for Ovarian Cancer Ovarian Cancer genetic testing?
Patients may qualify for Ovarian Cancer if they meet the program's eligibility criteria:
- (Note: This program does not require an outside provider to initiate testing. Color’s clinical team handles authorization.)
- Providers may become involved after testing, when patients share results or need follow-up evaluation.
- Providers who receive results through their patients may use them to guide counseling, surveillance, or treatment decisions.
- No action is required from providers to order testing — Color’s internal clinician network reviews and approves all test requests submitted through the program.
See an issue with this program?